To the Editor: In their report on ARCH (the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk), Saag and colleagues (Oct. 12 issue)1 report that postmenopausal women with osteoporosis who received 12 months of treatment with romosozumab, an antisclerostin antibody, followed by alendronate had a significantly lower risk of fracture than did those who received alendronate alone.1 However, there was a higher rate of serious cardiovascular adverse events in the romosozumab group than in the alendronate group (2.5% vs. 1.9%), including a higher rate of cardiac ischemic and cerebrovascular events (0.8% vs. 0.3%). Those findings were not . . .

中文翻译：

---

Romosozumab 与阿仑膦酸钠与骨质疏松症女性骨折风险的比较

致编辑：在 ARCH（患有高风险骨质疏松症的绝经后女性主动控制骨折研究）的报告中，Saag 及其同事（10 月 12 日）1 报告说，患有骨质疏松症的绝经后女性接受了 romosozumab 12 个月的治疗与单独接受阿仑膦酸钠治疗的患者相比，使用抗硬化素抗体，然后使用阿仑膦酸钠治疗的骨折风险显着降低。1 然而，罗莫索珠单抗组的严重心血管不良事件发生率高于阿仑膦酸钠组（2.5% vs. 2.5%）。 1.9%），包括较高的心脏缺血和脑血管事件发生率（0.8% vs. 0.3%）。这些发现并非如此。。。